Literature DB >> 27885826

Posterior reversible encephalopathy syndrome due to combination of vemurafenib and cobimetinib for metastatic melanoma.

Feriel Boukari1, Pierre Michel Dugourd1, Madleen Chassang2, Lydiane Mondot3, Thierry Passeron1,4, Jean-Philippe Lacour1, Henri Montaudie1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27885826     DOI： 10.1111/pcmr.12562

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN： 1755-1471            Impact factor:   4.693


× No keyword cloud information.
  3 in total

Review 1.  Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2017-05       Impact factor: 5.606

Review 2.  MicroRNA-Directed Cancer Therapies: Implications in Melanoma Intervention.

Authors:  Anita Thyagarajan; Ahmed Shaban; Ravi Prakash Sahu
Journal:  J Pharmacol Exp Ther       Date:  2017-10-20       Impact factor: 4.030

3.  Mepolizumab-Induced Posterior Reversible Encephalopathy Syndrome (PRES), a new patient report.

Authors:  Vikram V Puram; Dana Ghazaleh; Apameh Salari; Kaci McCleary; Gerald Moriarty; Kendall Nichols; Malik Ghannam; Kevin Brown; Brent Berry
Journal:  BMC Neurol       Date:  2022-08-25       Impact factor: 2.903
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.